论文部分内容阅读
目的探讨丹红注射液联合甲钴胺治疗糖尿病周围神经病变临床疗效和安全性,旨在为规范糖尿病周围神经病变的治疗提供参考依据。方法随机选择2010年1月至2012年1月在我院糖尿病科住院治疗的200例糖尿病周围神经病变患者为研究对象,应用随机数字表法将本研究入选患者分为两组,即对照组和实验组,对照组患者给予甲钴胺,实验组患者则在上述治疗的基础上加用丹红注射液进行治疗,观察对照组和实验组患者临床疗效和不良反应发生情况。结果实验组患者治疗总有效率(97.00%)明显高于对照组患者的(90.00%),差异有统计学意义(P<0.05),且对照组和实验组患者均未见全身性过敏反应、头痛、出汗和发热等药物不良反应,血尿常规、血糖血脂、电解质和肝肾功能等检查也未见明显异常,对照组和实验组患者在不良反应发生率差异无统计学意义(P>0.05)。结论丹红注射液联合甲钴胺治疗糖尿病周围神经病变临床疗效确切,安全可靠,不良反应少,值得进一步推广运用。
Objective To investigate the clinical efficacy and safety of Danhong injection combined with mecobalamin in the treatment of diabetic peripheral neuropathy, and to provide a reference for regulating the treatment of diabetic peripheral neuropathy. Methods From January 2010 to January 2012, 200 diabetic peripheral neuropathy patients hospitalized in Diabetes Department of our hospital were randomly divided into two groups: control group and Patients in the experimental group and the control group were treated with mecobalamin. Patients in the experimental group were treated with Danhong injection on the basis of the above treatment, and the clinical efficacy and adverse reactions in the control group and the experimental group were observed. Results The total effective rate (97.00%) in the experimental group was significantly higher than that in the control group (90.00%), the difference was statistically significant (P <0.05), and no systemic allergic reaction was found in the control group and the experimental group. Headache, sweating and fever and other adverse drug reactions, blood tests, blood glucose, electrolytes and liver and kidney function tests showed no significant abnormalities in the control group and experimental group patients in the incidence of adverse reactions was no significant difference (P> 0.05 ). Conclusion Danhong injection combined with mecobalamin for the treatment of diabetic peripheral neuropathy has definite clinical curative effect, safe and reliable, with few adverse reactions, which deserves further promotion and application.